Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Current Pharmaceutical Design|June 10, 2008
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's diseasePatrizia Popoli, David Blum, Maria Rosaria Domenici, et al.Acta Neuropathologica|April 12, 2015
Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivoSylvie Burnouf, Marianna Karina Gorsky, Jacqueline Dols, et al.Scientific Reports|March 5, 2016
Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivoMarianna Karina Gorsky, Sylvie Burnouf, Jacqueline Dols, et al.Transfusion|January 4, 2012
Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factorThierry Burnouf, Ya-Po Kuo, David Blum, et al.Neurobiology of Aging|December 3, 2014
Rescue of impaired late-phase long-term depression in a tau transgenic mouse modelTariq Ahmed, David Blum, Sylvie Burnouf, et al.Scientific Reports|September 1, 2017
Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicityMarianna Karina Gorsky, Sylvie Burnouf, Oyinkan Sofola-Adesakin, et al.Current Alzheimer Research|January 26, 2012
Hippocampal BDNF expression in a tau transgenic mouse modelSylvie Burnouf, Karim Belarbi, Laetitia Troquier, et al.Current Alzheimer Research|April 10, 2009
Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's diseaseKarim Belarbi, Katharina Schindowski, Sylvie Burnouf, et al.Scientific Reports|March 16, 2016
Deletion of endogenous Tau proteins is not detrimental in DrosophilaSylvie Burnouf, Sebastian Grönke, Hrvoje Augustin, et al.Current Alzheimer Research|January 26, 2012
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approachLaetitia Troquier, Raphaelle Caillierez, Sylvie Burnouf, et al.Pageof 2